PURPOSE: EWS-FLI1 fusion type, p53 mutation, and homozygous deletion of p16/p14ARF have each been shown to be prognostically significant in Ewing sarcoma (ES). We provide the first combined prognostic analysis of these three molecular parameters in ES. PATIENTS AND METHODS: We studied 60 patients with ES (stage: localized in 54, metastatic in six). All cases were confirmed to contain the EWS-FLI1 (29 type 1, 12 type 2, 14 other types) or EWS-ERG fusions (five cases). Homozygous deletion of p16/p14ARF, and p53 mutations were determined by fluorescent in situ hybridization and Affymetrix (Santa Clara, CA) p53 GeneChip microarray hybridization, respectively. RESULTS: Eight cases (13.3%) contained point mutations of p53, and eight cases (13.3%) showed p16/p14ARF deletion, including one case with both alterations. Among 32 cases with data on histologic chemoresponse, all 10 with alterations in p53 or p16/p14ARF showed a poor chemoresponse (P = .03). Variables predicting poorer overall survival included p53 mutation alone (P < .001), either p53 or p16/p14ARF alteration (P < .001), and stage (P < .01). In multivariate analysis, alterations of p53 and/or p16/p14ARF as a single variable, was the most adverse prognostic factor (P < .001), followed by stage (P = .04). In a multivariate analysis with alterations of p53 and p16/p14ARF as separate variables, both were significant (P < .001 and P = .03, respectively). Six cases with p16/p14ARF deletion were also studied for co-deletion of the contiguous methylthioadenosine phosphorylase gene, and this was detected in four cases. CONCLUSION: Alterations in p53 or p16/p14ARF are found in a fourth of ES cases and define a subset with highly aggressive behavior and poor chemoresponse.
PURPOSE:EWS-FLI1 fusion type, p53 mutation, and homozygous deletion of p16/p14ARF have each been shown to be prognostically significant in Ewing sarcoma (ES). We provide the first combined prognostic analysis of these three molecular parameters in ES. PATIENTS AND METHODS: We studied 60 patients with ES (stage: localized in 54, metastatic in six). All cases were confirmed to contain the EWS-FLI1 (29 type 1, 12 type 2, 14 other types) or EWS-ERG fusions (five cases). Homozygous deletion of p16/p14ARF, and p53 mutations were determined by fluorescent in situ hybridization and Affymetrix (Santa Clara, CA) p53 GeneChip microarray hybridization, respectively. RESULTS: Eight cases (13.3%) contained point mutations of p53, and eight cases (13.3%) showed p16/p14ARF deletion, including one case with both alterations. Among 32 cases with data on histologic chemoresponse, all 10 with alterations in p53 or p16/p14ARF showed a poor chemoresponse (P = .03). Variables predicting poorer overall survival included p53 mutation alone (P < .001), either p53 or p16/p14ARF alteration (P < .001), and stage (P < .01). In multivariate analysis, alterations of p53 and/or p16/p14ARF as a single variable, was the most adverse prognostic factor (P < .001), followed by stage (P = .04). In a multivariate analysis with alterations of p53 and p16/p14ARF as separate variables, both were significant (P < .001 and P = .03, respectively). Six cases with p16/p14ARF deletion were also studied for co-deletion of the contiguous methylthioadenosine phosphorylase gene, and this was detected in four cases. CONCLUSION: Alterations in p53 or p16/p14ARF are found in a fourth of ES cases and define a subset with highly aggressive behavior and poor chemoresponse.
Authors: Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi Journal: Nat Rev Cancer Date: 2011-07-14 Impact factor: 60.716
Authors: Aaron Cooper; John van Doorninck; Lingyun Ji; Darren Russell; Marc Ladanyi; Hiroyuki Shimada; Mark Krailo; Richard B Womer; Jessie Hao-ru Hsu; Dafydd Thomas; Timothy J Triche; Richard Sposto; Elizabeth R Lawlor Journal: Clin Cancer Res Date: 2010-11-03 Impact factor: 12.531
Authors: Neerav N Shukla; Juber A Patel; Heather Magnan; Ahmet Zehir; Daoqi You; Jiabin Tang; Fanli Meng; Aliaksandra Samoila; Emily K Slotkin; Srikanth R Ambati; Alexander J Chou; Leonard H Wexler; Paul A Meyers; Ellinor I Peerschke; Agnes Viale; Michael F Berger; Marc Ladanyi Journal: JCO Precis Oncol Date: 2017-05-23
Authors: Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick Journal: Mol Cell Biol Date: 2013-09-16 Impact factor: 4.272
Authors: Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: R L Randall; S L Lessnick; K B Jones; L G Gouw; J E Cummings; L Cannon-Albright; J D Schiffman Journal: J Oncol Date: 2010-03-15 Impact factor: 4.375